ANIP
ANI Pharmaceuticals, Inc.
$77.65
Platform & Compounding FCF
85%
Two-stage FCF DCF
Strong
·
Conviction
Undervalued
Trading 61.8% below fair value
You pay
$77.65
Bear
$113.17
Fair
$203.34
Bull
$314.64
Bear
$113.17
+45.7%
12% stage 1 growth, 11% discount
Fair
$203.34
+161.9%
19% stage 1 growth, 11% discount
Bull
$314.64
+305.2%
25% stage 1 growth, 11% discount
Key Value Driver
FCF growth rate (19% base case)
Terminal Value % of EV
46%
Implied Market Multiple
14.7x
Market is pricing in (growth)
4.9%
vs 19.3% base
Summary
Our base-case estimate uses a two-stage discounted cash flow model based on free cash flow. We then blend that result with the average analyst price target of $91.00 from 10 analysts, using a 20% weight on analyst consensus. That produces an estimated intrinsic value of $203.34 per share.
Warnings
Stock-based employee pay equals 48% of profits. This dilutes existing shareholders, so cash flow alone overstates what owners really earn.
Wall Street's average price target is $91.00 (from 10 analysts). Our estimate is 154% above the consensus -- consider that gap carefully.
Key Risks
- P/E alone misleads — earnings depressed by growth investment
- Cyclical or commodity businesses may be misclassified as platforms
- Terminal value dominance suggests sensitivity to long-run assumptions